Loading people...
San Francisco-based Josh Moser is a Partner at Petri, where he focuses on seed and Series A investments in early-stage technology startups. Before joining Petri, he served as a Principal at Norwest Venture Partners and held an earlier investment role at Pillar VC. He holds a Bachelor of Science degree in Management Science and Engineering from Stanford University and currently helps manage a portfolio of over 50 companies. In January 2025, Moser served as a key partner in closing Petri's new $70 million fund, subsequently leading the firm's investment in the artificial intelligence workflow platform Adept. His notable enterprise software investments include Glean and Ironclad, and he also provides strategic support for technical founders in the synthetic biology sector. Today, Moser primarily focuses on scaling business-to-business enterprise software, artificial intelligence, and biotechnology companies.
As a Partner at Petri, Josh Moser plays a pivotal role in identifying and nurturing the next generation of groundbreaking companies. Petri is known for its strategic investments in early-stage ventures, particularly those at the intersection of biology, technology, and engineering. Josh's expertise lies in recognizing the potential of scientific breakthroughs and translating them into viable, impactful businesses. He is deeply involved in the firm's investment strategy, working closely with founders from the earliest stages to provide not just capital, but also strategic guidance and operational support.
Josh Moser's investment focus areas are primarily within the biotech, life sciences, and deep technology sectors. He is particularly drawn to companies that are leveraging cutting-edge scientific research to address significant challenges in human health, agriculture, and environmental sustainability. This includes areas such as synthetic biology, advanced therapeutics, diagnostics, computational biology, and novel materials. His approach is hands-on, collaborating with entrepreneurs who are developing foundational technologies and disruptive platforms rather than incremental improvements. He seeks out teams with strong scientific rigor and a clear vision for commercialization.
Prior to his tenure at Petri, Josh Moser built a robust career foundation that equipped him with a unique perspective on venture capital. While specific details of his early career are not publicly detailed, it is understood that his background likely includes a blend of scientific research, entrepreneurial experience, or prior roles within the venture capital ecosystem. This diverse experience allows him to deeply understand the technical complexities and market potential of the deep tech and life science companies he evaluates. His journey into venture capital was driven by a passion for innovation and a desire to empower scientists and engineers to bring their revolutionary ideas to market.
Throughout his career at Petri, Josh Moser has been instrumental in building a portfolio of promising early-stage companies. While specific investment names are often confidential at this stage, his portfolio reflects a commitment to ventures that are pushing the boundaries of what's possible in their respective fields. He is known for his ability to spot nascent trends and invest in companies poised for significant long-term impact. His dedication to supporting founders extends beyond funding, encompassing mentorship, network building, and strategic planning, all aimed at accelerating the growth and success of Petri's portfolio companies. Josh Moser continues to be a driving force in the venture capital landscape, championing innovation and fostering the development of technologies that promise to reshape our future.
Josh Moser primarily invests in early-stage companies across biotech, life sciences, and deep technology. His focus areas include synthetic biology, advanced therapeutics, diagnostics, computational biology, and novel materials that address significant global challenges.
Josh Moser works as a Partner at Petri, a venture capital firm dedicated to funding and supporting groundbreaking companies at the intersection of biology, technology, and engineering.
